High Evidence
Research Overview
CagriSema Research for Prediabetes
An evidence-based overview of research examining CagriSema in the context of prediabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
Subgroup analysis from REDEFINE-1 showed 88% of participants with prediabetes at baseline returned to normoglycemia with CagriSema treatment. This suggests potential for diabetes prevention in high-risk populations.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Prediabetes
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. CagriSema may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.